Medpage Today on MSN5mon
Cytokine Release Syndrome and Neurotoxicity After CAR T-Cell Therapy
The incidence of CRS has been reported to range from 57% to 93% and ICANS from 20% to 70%. The frequency and severity of ...
Healio7d
Siltuximab reduces severity of cytokine release syndrome, ICANS after CAR T-cell therapy
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
Oncology Nursing News12d
Communication and Education: Improving Patient Outcomes With Bispecific T-Cell Engager Therapies
One of the hardest lessons learned occurred after I inadvertently failed at communication and education before transferring a ...
CURE4d
Expert Explains the Side Effects of Ordspono in R/R Follicular Lymphoma
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
TipRanks on MSN4d
Lyra Therapeutics Reports 2024 Financial Results and Updates
Lyra Therapeutics, Inc. ( ($LYRA) ) has released its Q4 earnings. Here is a breakdown of the information Lyra Therapeutics, Inc. presented to its ...
CAR T-Cell Therapy Market Soars With Groundbreaking Innovations Growing At A CAGR Of 28.5%
The CAR T-cell therapy market size was valued at $2.6 billion in 2022 & is estimated to hit $35.9 billion by 2032, exhibiting a CAGR of 28 ...
Medscape13d
NHL: Are Bispecific Antibodies a Safe Treatment?
TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...